The Effects of Beta-Blockers on Leukocytes and the Leukocyte Subpopulation in Heart Failure Patients DOI Creative Commons
Anca Daniela Fărcaș, Mirela Anca Stoia,

Diana Larisa Mocan-Hognogi

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2907 - 2907

Published: Dec. 20, 2024

Background/Objectives: Some specific types of white blood cells (WBCs) and the neutrophil/lymphocyte ratio (NLR) are independent predictors outcome for heart failure (HF) patients. WBC redistribution is induced by catecholamines, therefore we evaluate how different beta-blockers (BBs) influence it. Methods: The HF patients were clinically evaluated, was drawn to measure N-Terminal pro–B-type natriuretic peptide (NT-proBNP), WBC-differential formula, etc. Results: On admission, 61.16% who used a BB had no significant difference in number lymphocytes (Lym) neutrophils (Neu), but NLR NT- proBNP significantly lower compared with those without BB. NT-proBNP correlated dose on admission treated Metoprolol (Met) as Carvedilol (Car). type responsible 6.1% 5.9% variability Lym Neu, respectively. Patients ≥100 mg Met/day higher number, not reduced NLR, doses. ≥25 Car/day greater Neu doses, increased NLR. Conclusions: However, both BBs same rehospitalization rate during 12 month follow-up an improved outcome.

Language: Английский

Proposed Novel Heart Failure Biomarkers and Their Association with Length of Hospital Stay and Mortality: A Retrospective Observational Pilot Study DOI Creative Commons
Liviu Cristescu,

Dragos-Gabriel Iancu,

Marius Mărușteri

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(5), P. 589 - 589

Published: Feb. 28, 2025

Background/Objectives: Chronic heart failure (CHF) remains a significant global health burden, with high morbidity, prolonged hospitalizations, and increased mortality. Traditional biomarkers such as NT-proBNP provide prognostic value; however, novel biomarker ratios may enhance risk stratification. This study evaluated the predictive utility of NT-proBNP-to-albumin ratio (NTAR), red cell distribution width-to-eGFR (RGR), width-to-fibrinogen (RFR) for hospital length stay (LOS), extended hospitalization (ELOS), in-hospital mortality, 6-month all-cause Methods: A retrospective observational pilot was conducted on 382 CHF admissions (2022-2024) comprehensive laboratory assessment. Biomarker performance assessed through uni- multivariate logistic regression, receiver operating characteristic curve, Cox proportional hazards stepwise methods analyses refining models. Results: NTAR RGR emerged predictors outcomes. demonstrated moderate correlation LOS (r = 0.45, p < 0.001) an independent predictor ELOS (AUC 0.697, OR 2.438, 0.001), outperforming NT-proBNP. Additionally, significantly predicted mortality 0.768, 4.461, 0.766, 4.185, 0.001). strongest 0.785, HR 2.18, 0.005), highlighting its role in renal dysfunction erythropoietic alterations CHF. The RFR observed value minimal. Conclusions: In our study, offered valuable underscoring interplay cardiac stress, nutritional status, function prognosis. Further multicenter validation is warranted these biomarkers.

Language: Английский

Citations

0
The systemic inflammation response index as risks factor for all-cause and cardiovascular mortality among individuals with respiratory sarcopenia DOI Creative Commons
Ying Liu,

Xuejun Yin,

Yutong Guo

et al.

BMC Pulmonary Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 26, 2025

Respiratory sarcopenia is associated with poor outcomes, yet effective biomarkers for risk stratification remain limited. This study investigates the associations between complete blood count (CBC)-derived inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), neutrophil-monocyte-to-lymphocyte (NMLR), and systemic inflammation response index (SIRI) both all-cause cardiovascular mortality in patients respiratory sarcopenia. We conducted a cohort analysis of 1,673 adults possible using data from National Health Nutrition Examination Survey (NHANES) 2007 to 2012, follow-up through December 31, 2019. Possible was assessed via peak expiratory flow rate (PEFR). Multivariable Cox regression models evaluated NLR, NMLR, SIRI, adjusted demographic, socioeconomic, health-related covariates. Additional CBC-derived (PLR, dNLR, MLR, SII) were analysed, mediation albumin's role as partial mediator mortality. Over median 116 months, 263 deaths occurred, 68 causes. Elevated SIRI significantly increased risks emerged strongest predictor, hazard ratios (HRs) 1.65 (95% CI, 1.23–2.22) 3.18 1.83–5.53) Albumin partially mediated relationship (12.1%). are sarcopenia, demonstrating highest predictive power. Integrating into clinical assessments may aid identifying high-risk patients, allowing targeted interventions.

Language: Английский

Citations

0
The value of neutrophil-to-lymphocyte ratio predicting cardiovascular outcomes for patients with diabetes: A meta-analysis DOI Creative Commons

Jiazhu Zhang,

Qi Bao,

Yingli Mao

et al.

Asian Journal of Surgery, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
The Effects of Beta-Blockers on Leukocytes and the Leukocyte Subpopulation in Heart Failure Patients DOI Creative Commons
Anca Daniela Fărcaș, Mirela Anca Stoia,

Diana Larisa Mocan-Hognogi

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2907 - 2907

Published: Dec. 20, 2024

Background/Objectives: Some specific types of white blood cells (WBCs) and the neutrophil/lymphocyte ratio (NLR) are independent predictors outcome for heart failure (HF) patients. WBC redistribution is induced by catecholamines, therefore we evaluate how different beta-blockers (BBs) influence it. Methods: The HF patients were clinically evaluated, was drawn to measure N-Terminal pro–B-type natriuretic peptide (NT-proBNP), WBC-differential formula, etc. Results: On admission, 61.16% who used a BB had no significant difference in number lymphocytes (Lym) neutrophils (Neu), but NLR NT- proBNP significantly lower compared with those without BB. NT-proBNP correlated dose on admission treated Metoprolol (Met) as Carvedilol (Car). type responsible 6.1% 5.9% variability Lym Neu, respectively. Patients ≥100 mg Met/day higher number, not reduced NLR, doses. ≥25 Car/day greater Neu doses, increased NLR. Conclusions: However, both BBs same rehospitalization rate during 12 month follow-up an improved outcome.

Language: Английский

Citations

0